Prognostic Value of Metabolic Tumor Volume on (11)C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma

Overview

Journal Nucl Med Mol Imaging

Publisher Springer

Date 2015 Nov 10

PMID 26550048

Citations 20

Authors

Min Young Yoo

Jin Chul Paeng

Gi Jeong Cheon

Dong Soo Lee

June-Key Chung

E Edmund Kim

Keon Wook Kang

Affiliations

Soon will be listed here.

Abstract

Purpose: C-11 methionine (MET) PET is commonly used for diagnosing high-grade glioma (HGG). Recently, volumetric analysis has been widely applied to oncologic PET imaging. In this study, we investigated the prognostic value of metabolic tumor volume (MTV) on MET PET in HGG.

Methods: A total of 30 patients with anaplastic astrocytoma (n = 12) and glioblastoma multiforme (n = 18) who underwent MET PET before treatment (surgery followed by chemo-radiotherapy) were retrospectively enrolled. Maximal tumor-to-normal brain ratio (TNRmax, maximum tumor activity divided by mean of normal tissue) and MTV (volume of tumor tissue that shows uptake >1.3-fold of mean uptake in normal tissue) were measured on MET PET. Adult patients were classified into two subgroups according to Radiation Therapy Oncology Group Recursive Partitioning Analysis (RTOG RPA) classification. Prognostic values of TNRmax, MTV and clinicopathologic factors were evaluated with regard to progression-free survival (PFS).

Results: Median PFS of all patients was 7.9 months (range 1.0-53.8 months). In univariate analysis, MTV (cutoff 35 cm(3)) was a significant prognostic factor for PFS (P = 0.01), whereas TNRmax (cutoff 3.3) and RTOG RPA class were not (P = 0.80 and 0.61, respectively). Treatment of surgical resection exhibited a borderline significance (P = 0.06). In multivariate analysis, MTV was the only independent prognostic factor for PFS (P = 0.03).

Conclusion: MTV on MET PET is a significant and independent prognostic factor for PFS in HGG patients, whereas TNRmax is not. Thus, performing volumetric analysis of MET PET is recommended in HGG for better prognostication.

Citing Articles

Differentiating high-grade glioma progression from treatment-related changes with dynamic [F]FDOPA PET: a multicentric study.

Rozenblum L, Zaragori T, Tran S, Morales-Martinez A, Taillandier L, Blonski M Eur Radiol. 2022; 33(4):2548-2560.

PMID: 36367578 DOI: 10.1007/s00330-022-09221-4.

Prognostic value of 11C-methionine volume-based PET parameters in IDH wild type glioblastoma.

van Dijken B, Ankrah A, Stormezand G, Dierckx R, van Laar P, van der Hoorn A PLoS One. 2022; 17(2):e0264387.

PMID: 35213602 PMC: 8880430. DOI: 10.1371/journal.pone.0264387.

Potential role of functional imaging in predicting outcome for patients treated with carbon ion therapy: a review.

Riva G, Imparato S, Savietto G, Pecorilla M, Iannalfi A, Barcellini A Br J Radiol. 2021; 94(1128):20210524.

PMID: 34520670 PMC: 8631012. DOI: 10.1259/bjr.20210524.

Effect of quantitative values on shortened acquisition duration in brain tumor C-methionine PET/CT.

Morimoto M, Kudomi N, Maeda Y, Kobata T, Oishi A, Matsumoto K EJNMMI Phys. 2021; 8(1):34.

PMID: 33788057 PMC: 8012475. DOI: 10.1186/s40658-021-00379-2.

Prognostic Significance of Metabolic Parameters by F-FDG PET/CT in Thymic Epithelial Tumors.

Lee J, Cho Y, Kim J, Shim Y, Lee K, Choi J Cancers (Basel). 2021; 13(4).

PMID: 33572388 PMC: 7916204. DOI: 10.3390/cancers13040712.

References

Kobayashi K, Hirata K, Yamaguchi S, Manabe O, Terasaka S, Kobayashi H . Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients. Eur J Nucl Med Mol Imaging. 2015; 42(7):1071-80. DOI: 10.1007/s00259-015-3046-1. View

Kracht L, Miletic H, Busch S, Jacobs A, Voges J, Hoevels M . Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004; 10(21):7163-70. DOI: 10.1158/1078-0432.CCR-04-0262. View

Weller M, Felsberg J, Hartmann C, Berger H, Steinbach J, Schramm J . Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009; 27(34):5743-50. DOI: 10.1200/JCO.2009.23.0805. View

Galldiks N, Ullrich R, Schroeter M, Fink G, Jacobs A, Kracht L . Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging. 2009; 37(1):84-92. PMC: 2791473. DOI: 10.1007/s00259-009-1219-5. View

Im H, Pak K, Cheon G, Kang K, Kim S, Kim I . Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging. 2014; 42(2):241-51. DOI: 10.1007/s00259-014-2903-7. View

Galldiks N, Kracht L, Berthold F, Miletic H, Klein J, Herholz K . [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol. 2009; 96(2):231-9. PMC: 2808525. DOI: 10.1007/s11060-009-9953-x. View

Kim Y, Cheon G, Paeng J, Cho J, Kwak C, Kang K . Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization. Eur J Nucl Med Mol Imaging. 2015; 42(8):1247-56. DOI: 10.1007/s00259-015-3026-5. View

Kim S, Chung J, Im S, Jeong J, Lee D, Kim D . 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2004; 32(1):52-9. DOI: 10.1007/s00259-004-1598-6. View

Galldiks N, Dunkl V, Kracht L, Vollmar S, Jacobs A, Fink G . Volumetry of [¹¹C]-methionine positron emission tomographic uptake as a prognostic marker before treatment of patients with malignant glioma. Mol Imaging. 2012; 11(6):516-27. View

10.

Pirotte B, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O . Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery. 2009; 64(3):471-81. DOI: 10.1227/01.NEU.0000338949.94496.85. View

11.

Im H, Kim Y, Kim Y, Lee J, Lee W, Kim S . Usefulness of Combined Metabolic-Volumetric Indices of (18)F-FDG PET/CT for the Early Prediction of Neoadjuvant Chemotherapy Outcomes in Breast Cancer. Nucl Med Mol Imaging. 2014; 47(1):36-43. PMC: 4035214. DOI: 10.1007/s13139-012-0181-5. View

12.

Grosu A, Weber W, Riedel E, Jeremic B, Nieder C, Franz M . L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 63(1):64-74. DOI: 10.1016/j.ijrobp.2005.01.045. View

13.

Okubo S, Zhen H, Kawai N, Nishiyama Y, Haba R, Tamiya T . Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol. 2010; 99(2):217-25. DOI: 10.1007/s11060-010-0117-9. View

14.

Shishido H, Kawai N, Miyake K, Yamamoto Y, Nishiyama Y, Tamiya T . Diagnostic Value of 11C-Methionine (MET) and 18F-Fluorothymidine (FLT) Positron Emission Tomography in Recurrent High-Grade Gliomas; Differentiation from Treatment-Induced Tissue Necrosis. Cancers (Basel). 2013; 4(1):244-56. PMC: 3712687. DOI: 10.3390/cancers4010244. View

15.

Kim Y, Kim S, Paeng J, Lee H . Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma. Eur J Radiol. 2013; 83(1):231-5. DOI: 10.1016/j.ejrad.2013.09.031. View

16.

Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H . Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol. 2008; 29(6):1176-82. PMC: 8118839. DOI: 10.3174/ajnr.A1008. View

17.

De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M . Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg. 2001; 95(5):746-50. DOI: 10.3171/jns.2001.95.5.0746. View

18.

Singhal T, Narayanan T, Jain V, Mukherjee J, Mantil J . 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol. 2007; 10(1):1-18. DOI: 10.1007/s11307-007-0115-2. View

19.

Stupp R, Brada M, van den Bent M, Tonn J, Pentheroudakis G . High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii93-101. DOI: 10.1093/annonc/mdu050. View

20.

Lamborn K, Chang S, Prados M . Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 2004; 6(3):227-35. PMC: 1871999. DOI: 10.1215/S1152851703000620. View